JAK-IN-17

JAK-IN-17

• UNSPSC Description: JAK-IN-17 is a potent inhibitor of JAK. JAK-IN-17 is useful for the research of multiple diseases, particularly ocular, skin, and respiratory diseases (extracted from patent WO2021185305A1, compound 9-1)[1].
• Target Antigen: JAK
• Type: Reference compound
• Related Pathways: Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt
• Applications: COVID-19-immunoregulation
• Field of Research: Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/jak-in-17.html
• Solubility: 10 mM in DMSO
• Smiles: CC([C@@H]([C@H](C(O)=O)O)O)=O.CCC1=CC(O)=C(C=C1C2=CC(F)=C3C(NN=C3C4=NC5=C(N4)CCN(C5)C(CN6CCO[C@H](C6)C)=O)=C2)F
• Molecular Weight: 684.69
• References & Citations: [1]Zhang Chen, et al. An indazole derivative and its application in medicine. Patent WO2021185305A1.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported